Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
ERK 底物结合域在骨髓增生性肿瘤发病机制中的不同功能
基本信息
- 批准号:10719088
- 负责人:
- 金额:$ 70.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-06 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:Active SitesAddressAdenosine TriphosphateAttenuatedAutomobilesBindingCBL geneCRISPR screenCandidate Disease GeneCell Culture TechniquesClustered Regularly Interspaced Short Palindromic RepeatsDNA RepairDataDiseaseDisease ProgressionDockingF Box DomainFailureGrowthHealthHumanImpairmentIn VitroInterventionJAK2 geneKnock-in MouseKnowledgeMAP Kinase GeneMAPK1 geneMAPK3 geneMalignant - descriptorMalignant NeoplasmsMediatingMental DepressionModelingMolecularMutant Strains MiceMyeloproliferative diseaseOncogenesOncogenicPTPN11 genePathogenesisPathway interactionsPhosphotransferasesPlayPolycythemia VeraRUNX1 geneRoleSeriesSignal TransductionSiteSubstrate InteractionTestingTherapeuticTherapeutic InterventionValidationWorkXenograft Modelattenuationcancer cellcandidate identificationdriver mutationefficacy evaluationgenetic approachin vivoin vivo Modelinhibitorinsightmelanomamutant mouse modelnovelnovel therapeutic interventionpharmacologicpreservationrestraintsenescencesmall moleculetargeted treatmenttherapeutically effectivetime usetumortumor progressionubiquitin ligase
项目摘要
PROJECT SUMMARY/ABSTRACT
The Ras/MAPK pathway is activated in 85% of human cancer. Nevertheless, attempts to target Ras/MAPK
signaling have produced only limited efficacy. We hypothesize that one reason for the failure to successfully
target this pathway is that the targeting efforts have focused on the active sites of kinases in this cascade, which
has failed to provide long-lasting benefit. We hypothesize that the failure of this approach results from two
causes: 1) Active site inhibitors, which resemble adenosine triphosphate (ATP), must overcome the exceedingly
high cytosolic ATP levels in cancer cells; and 2) critical kinases in this cascade (e.g., ERK1/2) have distinct
substrate interactions domains that can perform antagonistic roles in regulating cancer progression.
Consequently, active-site focused inhibition is akin to simultaneous depression of the accelerator and brake
pedals of an automobile. We hypothesize that a more successful approach will be to develop inhibitors which
preserve kinase activity, but divert it exclusively to “brake pedal” substrates. In support, we have demonstrated
that the two substrate binding domains of ERK2, termed the D and DPB domains, play opposing roles in the
pathogenesis of JAK2-kinase driven myeloproliferative neoplasms (MPN). Indeed, the DBP and D domains act
like brake and accelerator pedals, opposing and promoting disease progression, respectively. Consequently,
pharmacologic attenuation of the accelerator pedal (D-domain) or its substrates should impair tumor progression
more potently than active site inhibition, because it selectively interferes with the disease promoting activity of
ERK2, while preserving the tumor suppressive function of the DBP-domain. While we have compelling evidence
for the opposing roles of the ERK2-D and DBP domains, the molecular basis for their action remains unclear
and this is an impediment to developing effective, pharmacologic interventions focused on the ERK2 D domain.
We now seek to address this gap in knowledge according to the following aims. We will: 1) Assess the generality
of the opposing functions of the ERK2-D and DBP domains in the pathogenesis of distinct MPN subtypes; 2)
Understand the mechanistic basis by which the ERK2-D and DBP domains exert their distinct functions; and 3)
Assess the efficacy of pharmacologic targeting of the ERK2-D domain and/or its targets in inhibiting cancer
progression. Through these efforts we expect to bring new insights into the role of ERK2 substrate binding
modules in regulating cancer progression and how to exploit this information therapeutically. While we begin with
MPN, these findings may have far reaching implications for other Ras/MAPK driven cancers.
项目总结/摘要
Ras/MAPK通路在85%的人类癌症中被激活。然而,针对Ras/MAPK的尝试
信号传导仅产生有限的功效。我们假设,一个原因,失败的成功,
靶向该途径的另一个重要原因是靶向工作集中在该级联中激酶的活性位点,
未能提供持久的好处。我们假设这种方法的失败来自两个方面
原因:1)活性位点抑制剂,类似于三磷酸腺苷(ATP),必须克服
癌细胞中较高的胞质ATP水平;和2)该级联中的关键激酶(例如,ERK 1/2)具有明显的
底物相互作用结构域可以在调节癌症进展中发挥拮抗作用。
因此,活性部位集中抑制类似于同时踩下油门和刹车
汽车的踏板。我们假设,一个更成功的方法将是开发抑制剂,
保留激酶活性,但将其专门转移到“刹车踏板”底物。为了表示支持,我们已经证明
ERK 2的两个底物结合结构域,称为D和DPB结构域,在细胞凋亡中起相反的作用。
JAK 2-激酶驱动的骨髓增生性肿瘤(MPN)的发病机制。事实上,DBP和D结构域
就像刹车和加速踏板,分别阻止和促进疾病的发展。因此,委员会认为,
加速器踏板(D-结构域)或其底物的药理学衰减应会损害肿瘤进展
比活性位点抑制更有效,因为它选择性地干扰疾病促进活性,
ERK 2,同时保留DBP结构域的肿瘤抑制功能。虽然我们有确凿的证据
对于ERK 2-D和DBP结构域的相反作用,其作用的分子基础仍不清楚
并且这是开发集中于ERK 2 D域的有效的药理学干预的障碍。
我们现在根据以下目标寻求解决这一知识差距。我们将:1)评估一般性
ERK 2-D和DBP结构域在不同MPN亚型发病机制中的相反功能; 2)
理解ERK 2-D和DBP结构域发挥其独特功能的机制基础;以及3)
评估ERK 2-D结构域和/或其靶点的药理学靶向在抑制癌症中的功效
进展通过这些努力,我们期望为ERK 2底物结合的作用带来新的见解。
调节癌症进展的模块以及如何在治疗上利用这些信息。当我们开始
MPN,这些发现可能对其他Ras/MAPK驱动的癌症具有深远的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TOMASZ SKORSKI其他文献
TOMASZ SKORSKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TOMASZ SKORSKI', 18)}}的其他基金
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
致癌酪氨酸激酶抑制剂可消除 DNA 修复和对 PARP 抑制剂敏感的白血病
- 批准号:
10374000 - 财政年份:2020
- 资助金额:
$ 70.7万 - 项目类别:
MPN-inducing mutations as biomarkers of synthetic lethality
MPN 诱导突变作为合成致死率的生物标志物
- 批准号:
10444919 - 财政年份:2020
- 资助金额:
$ 70.7万 - 项目类别:
MPN-inducing mutations as biomarkers of synthetic lethality
MPN 诱导突变作为合成致死率的生物标志物
- 批准号:
10652426 - 财政年份:2020
- 资助金额:
$ 70.7万 - 项目类别:
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
致癌酪氨酸激酶抑制剂可消除 DNA 修复和对 PARP 抑制剂敏感的白血病
- 批准号:
10608045 - 财政年份:2020
- 资助金额:
$ 70.7万 - 项目类别:
MPN-inducing mutations as biomarkers of synthetic lethality
MPN 诱导突变作为合成致死率的生物标志物
- 批准号:
10174883 - 财政年份:2020
- 资助金额:
$ 70.7万 - 项目类别:
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia
正常 ABL1 激酶作为白血病的肿瘤抑制因子和治疗靶点
- 批准号:
9897628 - 财政年份:2017
- 资助金额:
$ 70.7万 - 项目类别:
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia
正常 ABL1 激酶作为白血病的肿瘤抑制因子和治疗靶点
- 批准号:
9315519 - 财政年份:2017
- 资助金额:
$ 70.7万 - 项目类别:
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
靶向 DNA 修复以根除 TKi 难治性/耐药性 CML 和 Ph ALL
- 批准号:
9884207 - 财政年份:2014
- 资助金额:
$ 70.7万 - 项目类别:
Targeting DNA repair to eradicate TKI-refractory/resistant CML
靶向 DNA 修复以根除 TKI 难治性/耐药性 CML
- 批准号:
8702641 - 财政年份:2014
- 资助金额:
$ 70.7万 - 项目类别:
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
靶向 DNA 修复以根除 TKi 难治性/耐药性 CML 和 Ph ALL
- 批准号:
10357886 - 财政年份:2014
- 资助金额:
$ 70.7万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 70.7万 - 项目类别:
Research Grant